Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial

BACKGROUND: Rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) is one of the effective chemotherapeutic regimens for patients with advanced stage marginal zone lymphoma (MZL). However, prognostic factors that affect the outcome of treatment for MZL are not well understood. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Jeongkuk, Kim, Won Seog, Kim, Jin Seok, Kim, Seok Jin, Lee, Jae Hoon, Hong, Jun Shik, Lee, Gyeong-Won, Oh, Sung Yong, Lee, Ji-Hyun, Yoon, Dok Hyun, Lee, Won-Sik, Kim, Hyo Jung, Kwak, Jae-Yong, Kang, Hye Jin, Jo, Jae-Cheol, Park, Yong, Lee, Ho Sup, Kim, Hyo-Jin, Suh, Cheolwon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641512/
https://www.ncbi.nlm.nih.gov/pubmed/29043235
http://dx.doi.org/10.5045/br.2017.52.3.200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641512/
https://www.ncbi.nlm.nih.gov/pubmed/29043235
http://dx.doi.org/10.5045/br.2017.52.3.200

Ejemplares similares